These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25311974)

  • 1. Non-antiplatelet effect of clopidogrel: improving endothelial function in Chinese healthy subjects with different CYP2C19 genotype.
    Zhang YZ; Chen BL; Zhang W; Cao X
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):22-6. PubMed ID: 25311974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.
    Song BL; Wan M; Tang D; Sun C; Zhu YB; Linda N; Fan HW; Zou JJ
    Clin Ther; 2018 Jul; 40(7):1170-1178. PubMed ID: 30017169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.
    Kim HS; Cho DY; Park BM; Bae SK; Yoon YJ; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    J Clin Pharmacol; 2014 Aug; 54(8):850-7. PubMed ID: 24214141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
    Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
    Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
    Yang J; Zhao HD; Tan J; Ding YL; Gu ZQ; Zou JJ
    Pharmazie; 2013 Mar; 68(3):183-6. PubMed ID: 23556336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY
    Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation.
    Salimi S; Lewis JP; Yerges-Armstrong LM; Mitchell BD; Saeed F; O'Connell JR; Perry JA; Ryan KA; Shuldiner AR; Parsa A
    J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27799230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
    Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
    PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.
    Mejin M; Tiong WN; Lai LY; Tiong LL; Bujang AM; Hwang SS; Ong TK; Fong AY
    Int J Clin Pharm; 2013 Aug; 35(4):621-8. PubMed ID: 23661171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology.
    Li P; Cao M; Liu L; Chen L; Liang S; Wang Y
    BMC Pharmacol Toxicol; 2024 Jun; 25(1):34. PubMed ID: 38845014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M; Kajiwara M; Hasegawa S
    J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
    Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
    Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
    Jinnai T; Horiuchi H; Makiyama T; Tazaki J; Tada T; Akao M; Ono K; Hoshino K; Naruse Y; Takahashi K; Watanabe H; Kita T; Kimura T
    Circ J; 2009 Aug; 73(8):1498-503. PubMed ID: 19531897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.